Revolution Medicines, Inc. (RVMD)
NASDAQ:RVMD
Want to see RVMD full AI Analyst Report?
RVMD Stock Chart & Stats
$148.63
$0.52(1.17%)
At close: 4:00 PM EST
$148.63
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$34.00 - $166.50
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.70M
Market Cap
$34.65B
Enterprise Value$33.54B
Total Cash (Recent Filing)$1.91B
Total Debt (Recent Filing)$437.27M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 12, 2026EPS Estimate
-1.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.11
Shares Outstanding212,596,470
10 Day Avg. Volume2,628,952
30 Day Avg. Volume2,704,751
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.63K
Enterprise Value/Ebitda-25.43
Forecast
1Y Price Target
$182.78Price Target Upside22.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-7.97
Revenue Forecast (FY)$97.99M
Bulls Say, Bears Say
Bulls Say
Transformative Phase III EfficacyA clearly positive Phase III that reduces risk of death by 60% and extends median OS establishes daraxonrasib as a potential practice‑changing therapy. This durable clinical advantage supports regulatory filings, uptake in guidelines, and sustainable commercial opportunity if approvals succeed.
Strong Pro Forma Cash RunwayA multi‑billion dollar pro forma cash position materially reduces near‑term financing risk and enables completion of registrational trials and commercial launch investments. This capital base supports multi‑year execution and preserves strategic optionality to fund follow‑ons.
Commercial And Regulatory BuildoutInvesting in field teams, regulatory engagement and expanded access programs shows durable commitment to commercialization readiness. These capabilities shorten time‑to‑market post‑approval and increase probability of capturing value across priority international markets.
Bears Say
Very High And Growing Cash BurnSustained, accelerating cash burn and large net losses imply material ongoing funding needs. Even with recent raises, persistent negative free cash flow requires continued financing or rapid commercial success, raising dilution risk and increasing execution pressure over the next several quarters.
Higher Structural Operating ExpenseElevated operating expense guidance and permanently higher stock comp signal a step‑up in fixed costs associated with commercial readiness. This raises the revenue hurdle to reach profitability and increases the company’s sensitivity to slower than expected product uptake.
Trial Complexity And Regulatory Timing RiskChanging SOC and crossover considerations complicate future registrational trials and statistical power, potentially delaying readouts or requiring larger trials. Uncertain global filing timelines add regulatory execution risk that can extend time to revenue and increase development expense.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines, Inc.’s price range in the past 12 months?
Revolution Medicines, Inc. lowest stock price was $34.00 and its highest was $166.50 in the past 12 months.
What is Revolution Medicines, Inc.’s market cap?
Revolution Medicines, Inc.’s market cap is $34.65B.
When is Revolution Medicines, Inc.’s upcoming earnings report date?
Revolution Medicines, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 51 days.
How were Revolution Medicines, Inc.’s earnings last quarter?
Revolution Medicines, Inc. released its earnings results on May 06, 2026. The company reported -$2.29 earnings per share for the quarter, missing the consensus estimate of -$1.836 by -$0.454.
Is Revolution Medicines, Inc. overvalued?
According to Wall Street analysts Revolution Medicines, Inc.’s price is currently Undervalued.
Does Revolution Medicines, Inc. pay dividends?
Revolution Medicines, Inc. does not currently pay dividends.
What is Revolution Medicines, Inc.’s EPS estimate?
Revolution Medicines, Inc.’s EPS estimate is -1.96.
How many shares outstanding does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has 212,596,470 shares outstanding.
What happened to Revolution Medicines, Inc.’s price movement after its last earnings report?
Revolution Medicines, Inc. reported an EPS of -$2.29 in its last earnings report, missing expectations of -$1.836. Following the earnings report the stock price went down -5.666%.
Which hedge fund is a major shareholder of Revolution Medicines, Inc.?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$182.78 (22.98% Upside)
$182.78 (22.98% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 808.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 22.5%
Last 30 Days ▲ 22.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
308.18%
12-Months-Change
Fundamentals
Return on Equity
-83.22%
Trailing 12-Months
Asset Growth
-4.72%
Trailing 12-Months
Company Description
Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
RVMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and strategic progress—most notably the practice‑changing RASolute 302 Phase III result (60% reduction in risk of death) and a large capital raise that materially strengthens the balance sheet—while candidly disclosing near‑term financial impacts from rapid program acceleration, elevated stock‑based compensation and higher operating expenses. Operational and regulatory timing uncertainties and trial design complexities were noted, but the program momentum, supportive data across multiple assets, and strong funding availability suggest the positives materially outweigh the headwinds.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$182.78
▲(22.98% Upside)
Technical Analysis
Ownership Overview
2.12% Insiders
18.58% Mutual Funds
50.08% Other Institutional Investors
14.98% Public Companies and Individual Investors